<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01572467</url>
  </required_header>
  <id_info>
    <org_study_id>ARAR12B2</org_study_id>
    <secondary_id>COG-ARAR12B2</secondary_id>
    <secondary_id>NCI-2012-00721</secondary_id>
    <secondary_id>ARAR12B2</secondary_id>
    <nct_id>NCT01572467</nct_id>
  </id_info>
  <brief_title>Studying Genes in Samples From Younger Patients With Ovarian or Testicular Sex Cord Stromal Tumors</brief_title>
  <official_title>DICER1 Mutations and miRNA in Ovarian and Testicular Sex Cord Stromal Tumors of Childhood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may&#xD;
      help doctors identify biomarkers related to cancer.&#xD;
&#xD;
      PURPOSE: This research trial is studying genes in tumor samples from younger patients with&#xD;
      ovarian or testicular sex cord stromal tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To assess the role of DICER1 mutations and miRNA pathways in the etiology and&#xD;
           progression of ovarian or testicular sex cord stromal tumors.&#xD;
&#xD;
      OUTLINE: Archived tumor tissue samples are analyzed for D1CER1 mutation and mRNA expression&#xD;
      by reverse-transcriptase polymerase chain reaction (RT-PCR) and laser micro dissector.&#xD;
      Results are then correlated with medical data, including age at diagnosis, diagnosis,&#xD;
      pathology report, presenting symptoms, family history, treatment, outcome, and length of&#xD;
      follow-up, when available.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between DICER1 mutations and miRNA pathways with outcomes using descriptive analysis</measure>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Childhood Germ Cell Tumor</condition>
  <condition>Leydig Cell Tumor</condition>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical chart review</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients With Ovarian or Testicular Sex Cord Stromal Tumors&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Fixed and frozen tissue samples from the ATBR01 B1 tissue bank and from the&#xD;
             International Pleuropulmonary Blastoma Registry, Children's Hospital of Boston, and&#xD;
             Massachusetts General Hospital&#xD;
&#xD;
          -  Tissue samples from patients diagnosed with:&#xD;
&#xD;
               -  Ovarian&#xD;
&#xD;
                    -  Sertoli-Leydig cell tumor&#xD;
&#xD;
                    -  Juvenile granulosa cell tumor&#xD;
&#xD;
                    -  Adult granulosa cell tumor&#xD;
&#xD;
                    -  Gynandroblastoma&#xD;
&#xD;
                    -  Sex cord stromal tumor with annular tubules&#xD;
&#xD;
                    -  Sex cord stromal tumor, undifferentiated&#xD;
&#xD;
                    -  Sertoli tumor&#xD;
&#xD;
                    -  Leydig tumor&#xD;
&#xD;
               -  Testicular:&#xD;
&#xD;
                    -  Granulosa cell tumor&#xD;
&#xD;
                    -  Sertoli tumor&#xD;
&#xD;
                    -  Leydig tumor&#xD;
&#xD;
                    -  Sertoli-Leydig&#xD;
&#xD;
                    -  Undifferentiated stromal tumor&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dana A. Hill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's National Research Institute</affiliation>
  </overall_official>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>April 5, 2012</study_first_submitted>
  <study_first_submitted_qc>April 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2012</study_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leydig cell tumor</keyword>
  <keyword>ovarian stromal cancer</keyword>
  <keyword>childhood malignant testicular germ cell tumor</keyword>
  <keyword>childhood malignant ovarian germ cell tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Sex Cord-Gonadal Stromal Tumors</mesh_term>
    <mesh_term>Leydig Cell Tumor</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

